Related Experiment Video
Updated: Jun 7, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Plasma concentrations of soluble CD40 ligand in smokers with acute myocardial infarction: a pilot study
Mehmet Kayrak1, Ahmet Bacaksiz, Mehmet S Ulgen
1Department of Cardiology, Selcuk University Meram School of Medicine, Akyokus Meram, 42090, Konya, Turkey.
Insights
Smoking significantly elevates CD40 ligand (CD40L) levels in patients with acute myocardial infarction (MI). This suggests smokers with MI face higher thrombotic risks, necessitating optimal antiplatelet therapy.
Area of Science:
- Cardiology
- Hematology
- Oncology
Background:
- Coronary artery disease (CAD) is a leading global cause of death.
- Smoking is a primary risk factor for CAD, increasing platelet aggregation and thrombus formation.
- CD40 ligand (CD40L), derived from activated platelets, plays a role in acute myocardial infarction (MI) thrombus formation.
Purpose of the Study:
- To evaluate soluble CD40 ligand (sCD40L) levels in smokers experiencing acute MI.
- To compare sCD40L levels between smokers and non-smokers with acute MI.
Main Methods:
- Enrolled 57 patients with acute MI (31 smokers, 26 non-smokers).
- Measured plasma soluble CD40L levels using a standard enzyme-linked immunosorbent assay (ELISA).
Main Results:
- Circulating CD40L levels were significantly higher in the smokers' group compared to non-smokers.
- Elevated CD40L indicates higher risk for cardiac events and potential benefit from GPIIb/IIIa antagonists.
Conclusions:
- Smokers with acute MI exhibit elevated CD40L levels.
- This elevation suggests an increased risk for thrombotic complications in smokers with acute MI.
- Optimal antiaggregant therapy is recommended for smokers with acute MI.
Abstract:
Coronary artery disease (CAD) is believed to be the single leading cause of death in both men and women in the world. Smoking is the most important risk factor for CAD. Smoking increases platelet aggregation and thrombus formation. CD40 ligand (CD40L) is a transmembrane glycoprotein derived from activated platelets. It participates in thrombus formation during the acute phase of acute myocardial infarction (MI). Elevation of CD40L identifies the patients who are at highest risk for cardiac events and who are likely to benefit from treatment with the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonists. The purpose of this study was to evaluate levels of CD40L in smokers with acute MI. Fifty-seven patients with acute MI were enrolled in this study. Thirty-one smokers were compared with 26 non-smokers. Soluble CD40L level in the plasma was determined by a standard enzyme-linked immunosorbent assay. Circulating levels of CD40L were higher in the smokers' group. Smokers with acute MI may have increased risk for thrombotic complications during acute MI, and optimal antiaggregant therapy should be administered.
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...